Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Still a Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $47.50, but opened at $51.80. Zealand Pharma A/S shares last traded at $51.80, with a volume of 130 shares.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ZLDPF shares. Berenberg Bank cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, Wolfe Research downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, Zealand Pharma A/S has an average rating of “Hold”.

Get Zealand Pharma A/S alerts:

View Our Latest Research Report on Zealand Pharma A/S

Zealand Pharma A/S Stock Up 2.6%

The firm’s 50 day simple moving average is $45.44 and its 200-day simple moving average is $49.76. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $3.71 billion, a price-to-earnings ratio of 3.84 and a beta of 0.88.

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.

See Also

• Five stocks we like better than Zealand Pharma A/S
• Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
• AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
• NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
• Apple’s Next iPhone Could Test How Much Pricing Power Is Left

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.